Catalog No.
Product Name
Application
Product Information
Citations
-
myeloperoxidase inhibitor
PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases. -
GPX4 inhibitor
ML-210??the most potent compound in the nitroisoxazole series?? is a selective covalent inhibitor of glutathione peroxidase 4 (GPX4) by binding the selenocysteine residue.- Ning Li, .et al. , J Ovarian Res, 2024, Feb 23;17(1):49 PMID: 38396022
-
MPO inhibitor
Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders. -
ferroptosis inducer
Solasonine is a naturally occurring steroidal glycoalkaloid isolated from *Solanum melongena* (eggplant), known for its anti-infective, anticancer, and neurogenesis-promoting properties. It acts as a ferroptosis inducer by disrupting the glutathione redox system through inhibition of glutathione peroxidase 4 (GPX4). By promoting ferroptotic cell death in hepatocellular carcinoma (HCC) cells, Solasonine serves as a valuable compound for investigating ferroptosis mechanisms and developing novel anticancer strategies. -
GPX4 PROTAC Degrader
PROTAC GPX4 degrader-1 functions as a targeted protein degradation agent specifically for GPX4. It exhibits a DC50 of 0.03 μM in HT1080 cells, demonstrating potent activity in promoting the degradation of GPX4. This compound is applicable in research exploring the role of GPX4 in various cellular processes and the therapeutic potentials of targeting antioxidant defenses in disease models. -
PROTAC Glutathione Peroxidase Degrader
NC-R17 is a non-covalent degrader targeting Glutathione Peroxidase 4 (GPX4) through the PROTAC mechanism, designed to induce ferroptosis in cancer cells. Exhibiting significant antitumor activity, NC-R17 facilitates the targeted degradation of GPX4, contributing to research in cancer biology and therapeutic strategies. The compound combines a Demethyl-RSL3 ligand for GPX4 with an E3 ubiquitin ligase ligand derived from Lenalidomide, connected by a specific PROTAC linker to enhance its biological activity. -
GPX4 Degrader
GDCNF-11 is a potent HIM-PROTAC degrader targeting GPX4, utilizing the chaperone protein HSP90 to facilitate degradation. This compound promotes the ubiquitination of GPX4, leading to reduced expression levels, which in turn induces ferroptosis in HT-1080 cells. GDCNF-11 has a DC50 value of 0.08 μM, making it a valuable tool for studying ferroptosis and GPX4-related pathways in various biological research applications. -
GPX4 Targeting AUTAC
GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader designed to selectively induce degradation of GPX4 through autophagy. By promoting the ubiquitination of GPX4 via E3 ligase TRAF6, it enhances the interaction with p62, facilitating the autophagy-dependent degradation process. GPX4-AUTAC has been shown to significantly induce ferroptosis and exhibit notable anti-cancer activity in breast cancer cells, breast cancer-derived organoids, and in the MDA-MB-231 tumor xenograft model. Additionally, it demonstrates potent synergistic effects when used in combination with drugs such as Sulfasalazine or traditional chemotherapy agents like Paclitaxel or Cisplatin. -
Glutathione Peroxidase Mimic
Ebselen derivative 1 is a potent glutathione peroxidase (GPx) mimic with oral activity, designed to provide protective effects against oxidative damage. It exhibits significant protective capabilities against cisplatin-induced hair cell (HC) damage, effectively mitigating oxidative stress, apoptosis, and ferroptosis in hair cells. This compound serves as a valuable tool for research into cisplatin-induced hearing loss and related oxidative stress pathways. -
GPX4 Inhibitor
GPX4-IN-11 is a potent inhibitor of GPX4, demonstrating a KD of 45.7 μM. This compound is significant in the study of ferroptosis, enabling researchers to investigate the mechanisms underlying oxidative stress and cell death. Its utility in various biological assays contributes to the understanding of GPX4's role in disease processes and potential therapeutic approaches. -
GPX4 Inhibitior
GPX4-IN-18 is a ferrocene-containing inhibitor targeting glutathione peroxidase 4 (GPX4), recognized for its role in inducing ferroptosis. This compound significantly elevates reactive oxygen species (ROS) and malondialdehyde (MDA) levels in OS-RC-2 clear cell renal carcinoma cells, demonstrating potent biological activity. In HT-1080 cells, GPX4-IN-18 exhibits an IC50 of 0.007 μM in the absence of ferrostatin-1, and 1.486 μM when ferrostatin-1 is present. Additionally, GPX4-IN-18 has been shown to reduce tumor volume and intratumoral GPX4 levels in xenograft models, making it a valuable tool for researching ferroptosis-related pathways. -
GPX4 Inhibitor
GPX4-IN-13 is a potent inhibitor of GPX4, targeting its role in cellular antioxidant defense mechanisms. This compound exhibits significant anticancer activity by promoting ferroptosis and reducing proliferation in thyroid cancer cells. It demonstrates inhibitory effects on the growth of various thyroid cancer cell lines, with IC50 values of 8.39 μM for N-thy-ori-3-1, 10.28 μM for MDA-T32, and 8.18 μM for MDA-T41. GPX4-IN-13 is instrumental for research in cancer biology and therapeutic development targeting GPX4-dependent pathways. -
GPX4 Inhibitor
GPX4-IN-12 is a non-covalent inhibitor of Glutathione Peroxidase 4 (GPX4), primarily targeting this enzyme to induce ferroptosis. This compound effectively inhibits cell proliferation in HT1080 cells, making it a valuable tool for studying the mechanisms of ferroptosis and its implications in cancer research. GPX4-IN-12 is suitable for investigations into oxidative stress and related pathways within various biological contexts. -
GPX4 Inhibitor
GPX4-IN-21 is a selective inhibitor of glutathione peroxidase 4 (GPX4), a key regulator in cellular redox homeostasis. This compound effectively induces ferroptosis by downregulating ferroptosis-related proteins, including SLC7A11, SLC11A2, and GPX4, leading to increased levels of reactive oxygen species (ROS) and malondialdehyde (MDA). GPX4-IN-21 demonstrates significant anti-proliferative activity and is useful for investigating therapeutic strategies in cancer research, particularly in models of melanoma. -
GPX4 Degrader
GPX4 degrader-1 (Compound RS-1) is a hydrophobic tagging (HyT)-mediated degrader specifically targeting GPX4, exhibiting a DC50 value of 8.9 nM in HT1080 cells. This compound effectively induces GPX4 degradation, promoting ferroptosis through the accumulation of lipid reactive oxygen species (ROS). Additionally, GPX4 degrader-1 has shown significant antitumor efficacy in preclinical murine mammary carcinoma models, making it a valuable tool for cancer research and therapeutic study. -
GPX4 PROTAC Degrader
PROTAC GPX4 degrader-4 selectively targets GPX4, functioning as a PROTAC degrader with a DC50 of 5.32 nM. This compound effectively inhibits the proliferation of RT4, T24, and J82 bladder cancer cell lines, exhibiting IC50 values of 0.09, 2.97, and 7.58 μM, respectively. PROTAC GPX4 degrader-4 promotes the accumulation of lipid reactive oxygen species (ROS) and triggers ferroptosis in T24 and RT4 cells. Additionally, it demonstrates significant antitumor efficacy in a T24 tumor-bearing BALB/c nude mouse model, making it a valuable tool for bladder cancer research. -
GPX4 Activator
GPX4 Activator 1 is an allosteric modulator that targets GPX4, demonstrating a Kd of 5.86 μM and an EC50 of 19.19 μM. This compound effectively enhances GPX4 activity, thereby inhibiting ferroptosis by preventing the accumulation of intracellular lipid peroxides induced by ferroptosis inducers. It serves as a valuable tool for researchers studying ferroptosis mechanisms and potential therapeutic interventions in diseases associated with oxidative stress. -
GPX4 Inhibitor
NPD4928 is a potent GPX4 inhibitor that enhances RSL3-dependent ferroptosis through its unique mechanism of action. By binding to ferroptosis suppressor protein 1 (FSP1), NPD4928 effectively inhibits its enzymatic activity, thereby promoting ferroptotic cell death. This compound is valuable for research applications focused on studying ferroptosis pathways and identifying potential therapeutic targets in cancer and neurodegenerative diseases. -
GPX4 Inhibitor
GPX4-IN-6 is a covalent inhibitor of GPX4, exhibiting an IC50 of 0.13 μM. This compound effectively induces ferroptosis, making it a valuable tool for studying mechanisms related to triple-negative breast cancer (TNBC). Its role in modulating oxidative stress pathways presents significant implications for cancer research and therapeutic development. -
GPX4 Inhibitor
JKE-1716 is a potent and selective inhibitor of glutathione peroxidase 4 (GPX4). It induces ferroptosis through the covalent modification of GPX4, making it a valuable tool for studying iron-dependent cell death mechanisms. This compound is applicable in research focusing on cancer biology, neurodegenerative diseases, and oxidative stress-related studies. -
GPX4 Inhibitor
RSL3-NH2 is a selective inhibitor of GPX4, a crucial regulator of lipid peroxidation and ferroptosis. By promoting ferroptosis in cancer cells, RSL3-NH2 serves as an effective tool for studying cell death pathways and cancer metabolism. Additionally, this compound can be utilized as a cytotoxic payload in the development of antibody-drug conjugates (ADCs), enhancing targeted therapeutic strategies in cancer research. -
GPX4 Inhibitor
GPX4-IN-9 is a selective inhibitor of glutathione peroxidase 4 (GPX4), effectively promoting ferroptosis under both in vitro and in vivo conditions. This compound demonstrates significant cytotoxic effects on pancreatic cancer cells, making it a valuable tool for cancer research. Its mechanisms of action offer insights into the role of GPX4 in cancer cell survival and potential therapeutic strategies targeting ferroptosis. -
GPX4 Inhibitor
GPX4-IN-19 is a potent inhibitor of GPX4, exhibiting an IC50 of 0.311 μM through covalent binding to the Sec 46 site. This compound demonstrates significant anti-proliferative effects with a high selectivity for inducing ferroptosis, characterized by intracellular Fe2+ accumulation and elevated levels of lipid peroxides (LPOs) and reactive oxygen species (ROS). GPX4-IN-19 is particularly relevant for research in Triple-Negative Breast Cancer (TNBC), as it induces ferroptosis and subsequent DNA damage. -
YAP-GPX4 Signaling Modulator
Pipecolic acid is a metabolite of lysine that acts as a YAP-GPX4 signaling modulator. It exhibits antioxidant properties and has been shown to reduce retinal vascular tube formation while mitigating ferroptosis. This compound enhances voltage-sensitive Ca2+ channel currents and can induce neuronal apoptosis, making it a valuable tool for research on diabetic retinopathy. Its ability to cross the blood-brain barrier further supports its application in neurological studies. -
Nrf2-Gpx4 Activator
Gingerenone A is an Nrf2-Gpx4 activator that triggers ferroptosis in liver tissue, demonstrating significant potential for therapeutic intervention in liver damage. This compound exhibits notable anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging properties observed in murine models, making it valuable for research in oxidative stress regulation and associated diseases. Its oral bioactivity further enhances its applicability in in vivo studies. -
GPX4 Inhibitor
JKE-1674 is a potent inhibitor of glutathione peroxidase 4 (GPX4), functioning through modulation of cellular redox status. This orally active compound, an analog of ML-210 with a structural modification to the nitroisoxazole ring, demonstrates strong cytotoxicity against LOX-IMVI cells, akin to that of ML-210. Notably, cell viability is restored upon treatment with ferroptosis inhibitors, underscoring its utility in studying ferroptotic cell death pathways and oxidative stress in various biological contexts. -
GPX4 Inhibitor
GPX4-IN-3 is a selective inhibitor of glutathione peroxidase 4 (GPX4), serving as a potent inducer of ferroptosis. At a concentration of 1 μM, GPX4-IN-3 demonstrates 71.7% inhibition of GPX4 activity. This compound is valuable for research applications focused on oxidative stress, cell death mechanisms, and potential therapeutic strategies against various cancers and neurodegenerative diseases. -
GPX4 Inhibitor
GPX4-IN-5 is a potent covalent inhibitor of GPX4, exhibiting an IC50 of 0.12 μM. This compound induces ferroptosis, demonstrating significant anti-tumor activity. GPX4-IN-5 is particularly relevant for research applications focused on triple-negative breast cancer (TNBC). -
GPX4 Activator
GPX4 Activator 2 is a potent activator of glutathione peroxidase 4 (GPX4), a key enzyme involved in reducing oxidative stress. It demonstrates significant cardioprotective effects and effectively inhibits cellular ferroptosis with an EC50 of 7.8 μM. This compound is valuable for research applications focused on myocardial injury and the mechanisms of ferroptosis in cardiovascular diseases. -
Glutathione Peroxidase Inhibitor
4-Methylesculetin is a coumarin derivative that functions as a potent inhibitor of glutathione peroxidase. This compound exhibits significant antioxidant and anti-inflammatory properties, effectively inhibiting myeloperoxidase activity. In research applications, 4-Methylesculetin demonstrates the ability to attenuate bone resorption by downregulating elevated levels of bone-related exoglycosidases, cathepsin D, and tartrate-resistant acid phosphatases. Additionally, it reduces the expression of pro-inflammatory markers such as TNF-α, IL-1β, IL-6, COX-2, and PGE2, making it a valuable tool for studying inflammatory diseases. -
PROTAC GPX4 Degrader
PROTAC GPX4 degrader-5 is a selective degrader targeting GPX4, with a DC50 of 28 nM. This compound effectively induces ferroptosis and enhances reactive oxygen species (ROS) levels while exhibiting low toxicity to normal cells. PROTAC GPX4 degrader-5 demonstrates significant anti-proliferative effects in various tumor cell lines, making it a valuable tool for cancer research. -
GPX4 Allosteric Activator
PKUMDL-LC-101-D04 is an allosteric activator of glutathione peroxidase 4 (GPX4), exhibiting a pEC50 value of 4.7. This compound effectively inhibits ferroptosis and reduces inflammatory responses, making it a valuable tool for research investigating oxidative stress and related pathologies. Its ability to modulate GPX4 activity highlights its potential applications in studies focused on cell survival and neuroprotection. -
Glutathione Peroxidase Inhibitor
4-Aminobenzohydrazide is a potent inhibitor of glutathione peroxidase, demonstrated to induce oxidative stress in neutrophils, with an IC50 value of 43.6 μM for reactive oxygen species (ROS) generation. This compound serves as a valuable tool for investigating oxidative stress-related mechanisms and has applications in subacute stroke research. Its ability to irreversibly inhibit myeloperoxidase further reinforces its utility in studying inflammatory processes and cellular responses. -
Glutathione Peroxidase
Glutathione Peroxidase (GSH-Px; EC 1.11.1.9) is an enzyme from the peroxidase family that catalyzes the reduction of hydrogen peroxide and lipid peroxides, utilizing reduced glutathione (GSH) to produce oxidized glutathione (GSSG). This enzyme plays a critical role in cellular defense against oxidative stress by scavenging reactive oxygen species. Glutathione Peroxidase is widely used in biochemical research to investigate antioxidant mechanisms and the cellular response to oxidative damage. -
Intermediate
GPX4-IN-2 is an intermediate compound related to GPX4-IN-1, which targets glutathione peroxidase 4 (GPX4). This compound exhibits antiproliferative activity, making it a valuable tool in cancer research. Its role in the exploration of GPX4's function and its potential as a therapeutic target in oncology can aid in the development of innovative cancer treatments. -
GPX4 Inhibitor
GPX4-IN-4 is a selective inhibitor of glutathione peroxidase 4 (GPX4). This compound demonstrates significant efficacy in disrupting GPX4 activity, leading to increased oxidative stress and cellular apoptosis. GPX4-IN-4 is particularly relevant for cancer research, as it can help elucidate the role of GPX4 in tumor growth and survival, providing insights for potential therapeutic strategies. -
GPX4-Inhibitor Affinity Probe
ML162-yne is a selective GPX4-inhibitor affinity probe that utilizes click chemistry for targeted interactions. Featuring an alkyne functional group, this reagent can participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling efficient conjugation with azide-containing molecules. This capability makes ML162-yne valuable for studying the role of GPX4 in various biological processes and for developing novel therapeutic strategies. -
Glutathione Peroxidase Inhibitor
Sorbifolin is a flavone glucoside that functions as a potent inhibitor of glutathione peroxidase. It exhibits myeloperoxidase inhibitory activity with an IC50 value of 19.2 nM, along with significant radical scavenging properties. Due to its ability to modulate oxidative stress-related pathways, Sorbifolin is valuable for research applications focusing on inflammatory diseases and redox homeostasis. -
GPX4 Inhibitor
GPX4-IN-15 is a specific inhibitor of GPX4, demonstrating a 19.8% inhibition at a concentration of 1 μM. This compound effectively inhibits the proliferation of various cancer cell lines, including MDA-MB-468, BT-549, and MDA-MB-231, with IC50 values of 0.86 μM, 0.96 μM, and 0.48 μM, respectively. GPX4-IN-15 is a valuable tool for researchers investigating the role of GPX4 in cancer biology and therapeutic resistance. -
GPX4 Inhibitor
GPX4-IN-17 is a selective inhibitor of GPX4, demonstrating potent cytotoxicity with an IC50 of 0.3 nM and high binding affinity (KD = 20.4 nM). This compound effectively inhibits tumor growth in xenograft models while exhibiting minimal cytotoxic effects on normal tissues. GPX4-IN-17 is a valuable tool for enhancing cancer chemotherapy and addressing tumor resistance, making it a significant reagent for antitumor research applications. -
GPX4 Inhibitor
GPX4-IN-1 is a potent inhibitor of glutathione peroxidase 4 (GPX4), a critical enzyme involved in cellular redox regulation. This compound exhibits significant antiproliferative activity, making it a valuable tool in cancer research. GPX4-IN-1 can be utilized to investigate mechanisms of cancer cell survival and sensitivity to oxidative stress, providing insights into targeted therapies for malignancies. -
GPX4 Activator
DEL-I25 is a potent activator of glutathione peroxidase 4 (GPX4), a critical enzyme involved in cellular antioxidant defense. This compound effectively protects cells from ferroptosis, a form of regulated cell death associated with oxidative stress. DEL-I25 is valuable in research applications focused on understanding ferroptosis mechanisms and developing therapeutic strategies for diseases related to oxidative damage. -
STIM1-TFR1 Protein Complex Inhibitor
STIM1-TFR1-IN-1 is an inhibitor of the STIM1-transferrin receptor 1 (TFR1) protein complex, exhibiting a binding affinity (Kd) of 2.18 μM to the STIM1-CD protein. This compound effectively disrupts the STIM1-TFR1 interaction, thereby decreasing TFR1-mediated iron uptake while inhibiting ferroptosis, lipid peroxidation, and reactive oxygen species (ROS) production. STIM1-TFR1-IN-1 also enhances glutathione peroxidase 4 (GPX4) activity and improves the glutathione/oxidized glutathione ratio, promoting neuroprotective effects and mitigating brain injury. This reagent is particularly relevant for studies focusing on intracerebral hemorrhage. -
Glutathione Peroxidase Activator
RC363 is a novel glutathione peroxidase (GPx) activator designed to enhance the levels and activity of GPx1. This compound demonstrates protective effects on mouse hippocampal cells and primary cortical neurons against glutamate-induced oxidative cell death, specifically ferroptosis. RC363 is valuable for research investigating oxidative stress and neuroprotection mechanisms. -
GPX4 Inhibitor
GPX4-IN-8 is a selective inhibitor of Glutathione Peroxidase 4 (GPX4), a key enzyme involved in cellular redox homeostasis. This compound exhibits significant antiproliferative activity, making it a valuable tool for research focusing on oxidative stress, ferroptosis, and cancer biology. GPX4-IN-8 can effectively facilitate investigations into the role of GPX4 in various disease models and therapeutic contexts. -
GPX4 Inhibitor
LOC1886 is a covalent inhibitor targeting glutathione peroxidase 4 (GPX4), crucial for regulating oxidative stress within cells. It exhibits robust biological activity that aids in the investigation of ferroptosis and related cell death pathways. This compound is particularly useful for research applications focused on cancer biology, neurodegenerative diseases, and the study of oxidative damage mechanisms. -
Nucleoside Metabolite
(R)-b-Aminoisobutyric acid is a nucleoside metabolite that serves as an effective amino donor. It plays a significant role in various biochemical pathways, making it valuable for studies on amino acid metabolism and nucleoside synthesis. This compound can be used in research applications focused on metabolic disorders and the regulation of nucleoside levels within cells.
